

**J. Behr** has received fees for speaking from Actelion Pharmaceuticals Ltd., Bayer-Schering Pharma, Boehringer-Ingelheim, Encysive, GSK, Pfizer, Lilly, Nycomed, InterMune, Novartis and MSD. J.B. has served as consultant/advisor for Actelion Pharmaceuticals Ltd., Bayer-Schering Pharma, Lilly, Pari-Pharma, GSK, InterMune, Pfizer, Optima and Gilead. J.B. has received research grants from Actelion Pharmaceuticals Ltd., Bayer-Schering, InterMune and Pari-Pharma. His attendance at international and national congresses has been sponsored by Actelion Pharmaceuticals Ltd., Boehringer-Ingelheim, AstraZeneca, Bayer and InterMune.

**R. Million-Rousseau** is a permanent employee at Actelion Pharmaceuticals Ltd, the sponsor of the MUSIC trial. She receives a salary and stock options from Actelion Pharmaceuticals Ltd according to her employment contract and receives reimbursement for attendance at relevant congresses or symposia as part of her training and development plan.

**A. Morganti** is a permanent employee at Actelion Pharmaceuticals Ltd, the sponsor of the MUSIC trial. She receives a salary and stock options from Actelion Pharmaceuticals Ltd according to her employment contract and receives reimbursement for attendance at relevant congresses or symposia as part of her training and development plan.

**L. Perchenet** is a permanent employee at Actelion Pharmaceuticals Ltd, the sponsor of the MUSIC trial. He receives a salary and stock options from Actelion Pharmaceuticals Ltd according to his employment contract and receives reimbursement for attendance at relevant congresses or symposia as part of his training and development plan.

**G. Raghu** has been a consultant for Actelion Pharmaceuticals Ltd., Boehringer-Ingelheim, Celgene, Centocor (Johnson and Johnson), Gilead, Geno-Sciences, Fibrogen, Sanofi-Aventis and Stromedix, and is a recipient of a research grant from National Institutes of Health, Bethesda, Maryland, USA to conduct IPF clinical studies.